Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9223934 | 0.81 | POLB (0.42) | POLBALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL2057989 | 0.77 | CA1 (0.35) | POLBALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL9217674 | 0.77 | TRPA1 (0.41) | ALDH1A1MAPTMAPK1TDP1SMN1; SMN2 | |
| SCHEMBL7033569 | 0.74 | TRPA1 (0.38) | ALDH1A1MAPTTDP1SMN1; SMN2TRPA1 | |
| SCHEMBL852173 | 0.74 | TRPA1 (0.38) | ALDH1A1TDP1SMN1; SMN2TRPA1ATM | |
| SCHEMBL9343766 | 0.74 | TRPA1 (0.38) | ALDH1A1MAPTTDP1SMN1; SMN2TRPA1 | |
| SCHEMBL10523368 | 0.74 | TRPA1 (0.38) | ALDH1A1TDP1SMN1; SMN2TRPA1ATM | |
| SCHEMBL6340796 | 0.74 | TRPA1 (0.43) | POLBALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL8038880 | 0.73 | GABRA1 (0.33) | TRPA1ATM | |
| SCHEMBL1470830 | 0.71 | TRPA1 (0.40) | ALDH1A1KMT2AMAPTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275427-B1 | Ruthenium-diamine complex and methods for producing optically active compounds | TAKASAGO PERFUMERY CO LTD (JP) | 2013-09-11 | — | — | EP | disclosed |
| US-8404879-B2 | Ruthenium-diamine complex and methods for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| EP-2258707-B1 | Ruthenium silyl-arene complexes, and method for production thereof | TAKASAGO PERFUMERY CO LTD (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-7880025-B2 | complexing trimethyl(4-methyl-1,4-cyclohexadienyl)silane with ruthenium chloride to produce RuCl2 [trimethyl (4-methyl-1,4-cyclohexadienyl) silane] | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2275427-A1 | Ruthenium-diamine complex and methods for producing optically active compounds | Takasago International Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009646-A1 | RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2258707-A1 | Ruthenium silyl-arene complexes, and method for production thereof | Takasago International Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20100298588-A1 | RUTHENIUM SILYL-ARENE COMPLEX , AND METHOD FOR PRODUCTION THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298588-A1 | RUTHENIUM SILYL-ARENE COMPLEX , AND METHOD FOR PRODUCTION THEREOF | SPR, LSS, SRI | POLB 4534/4885ALDH1A1 2369/4885KMT2A 3917/4885 |
| US-20110009646-A1 | RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | ADH5, AOC1, ADH1A | POLB 1131/4885ALDH1A1 54/4885KMT2A 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.